Latest news

Adalvo provides an update on Rifamycin SV MMX, an EU-approved product, with Marketing Authorizations (MAs) secured in selective countries.

Adalvo announces the restart of the DCP procedure for Mirabegron 50 mg prolonged-release tablets with an anticipated EU Marketing Authorisation Approval date in July 2024. Developed based on the reference brand...

Diabetic care presents a complex challenge, requiring diverse treatment options to improve patient outcomes effectively.  Adalvo's diabetes portfolio offers advanced therapies designed to address the underlying conditions of the disease. From...

Adalvo announces the restart of the DCP procedure for Desogestrel/Ethinylestradiol 150/20 micrograms film-coated tablets, with an anticipated EU approval date for August 2024.  Developed based on the reference brand Mercilon film-coated tablets,...

In Q1 2024, Adalvo successfully submitted a total of 329 Marketing Authorisation (MA) applications, spanning 55 countries and representing collaborative efforts with 31 strategic partners.  On top of this, Adalvo achieved...

Adalvo acknowledges and participates in World IP Day 2024, joining the global community in celebrating innovation and creativity in intellectual property (IP). This year's theme, "𝐈𝐏 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐒𝐃𝐆𝐬: 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠...

Adalvo is excited to announce the introduction of Apalutamide to our Oncology Portfolio. Based on the reference brand Erleada, Apalutamide, available in film-coated tablet form with strengths of 60mg and 240mg, is a...

Adalvo is strategically advancing in the development of Ceftazidime + Avibactam, a complex and differentiated antibiotic combination, aiming to be First To File in all major markets.  Based on the...

Adalvo proudly announces a significant milestone in its operational performance, setting a new record by releasing a total of 221 batches during March 2024, surpassing previous benchmarks by 42%. This achievement showcases...

Adalvo and Aristo Pharma proudly announce the successful launch of Pregabalin Prolonged Release Tablets in Germany, solidifying their position as the first to introduce this innovative medication in the European...

Adalvo proudly announces the addition of Mirabegron/Solifenacin Prolonged Release Tablets to our product list, set to be submitted for regulatory approval in Q1 2025. Developed in collaboration with one of our strategic...

Aztiq, a prominent healthcare investor led by Founder and Chairman Róbert Wessman, has finalized an agreement in Q1 2024 with Innobic (Asia) Company Limited (“Innobic”), the life science arm of...

Adalvo is pleased to announce the restart of the EU Marketing Authorisation Approval for Empagliflozin 10mg and 25mg film-coated tablets with an anticipated approval date in July 2024. Our product has...

Adalvo is thrilled to announce the successful launch of Desmopressin in multiple countries across Europe, in collaboration with key strategic partners. Developed based on the reference brand Minirin Melt from Ferring, Desmopressin...

Adalvo is delighted to announce the successful completion of the FED and Fasting Pilot BE Study for Fidaxomicin Film Coated Tablets 200mg. Developed in collaboration with one of our strategic partners,...

Adalvo proudly announces the addition of Alectinib 300, 450, and 600mg tablets to our product list. Our product, being developed based on the reference brand Alecensa 150mg hard capsules, will serve as...

Adalvo is pleased to announce the restart of the DCP procedure for Ethinylestradiol + Drospirenone 0.03 mg/3 mg, with an anticipated approval date in July 2024. Based on the reference brand...

Adalvo proudly announces the addition of Lenvatinib 4mg/ml Oral Solution to our product portfolio. Our product, developed based on the reference brand LENVIMA, serves as a vital treatment for Differentiated Thyroid...

Adalvo is delighted to announce the restart of the DCP procedure for Dalbavancin powder, with an estimated approval date in May 2024. This antibiotic niche product has been developed based on...

Adalvo is pleased to announce the successful Marketing Authorization (MA) approval of Pomalidomide Hard Capsules 1/2/3/4mg in Israel. Our product, based on the reference brand Imnovid, is indicated for the...

Adalvo proudly announces its recent induction into Medicines for Europe, a renowned association advancing the generic pharmaceutical sector.    As a member, Adalvo will play a pivotal role in shaping the future...